An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating...
Recent studies shed light on the safety and efficacy of diabetes medications GLP-1 receptor agonists, SGLT2 inhibitors, and DPP4 inhibitors were all scrutinized in new research presented at ENDO 2024. While most of the results were good news for the impact of medications for people with type 2 diabetes, clinicians prescribing these medications should be...
New research explores the impact of prediabetes on a Mexican population. According to a study presented at ENDO 2024, prediabetes increases the risk of dying before the age of 75, particularly due to heart disease, kidney disease, and acute diabetic complications in Mexican populations. The study’s author, Carlos A. Fermín-Martínez, MD, discusses his findings and...
All the Rage: Combatting Counterfeit Weight-Loss and Diabetes Drugs
As online ads abound for diabetes and obesity medications, endocrinologists should be prepared to talk to patients who may be attracted to GLP-1 drug lookalikes and supplements from questionable sources. GLP-1 agonists are a cultural phenomenon. Celebrities and social media influencers hyping the drugs’ weight-loss success has led to demand outstripping supply, resulting in shortages...
Unsolved Mysteries: After Four Decades, Daniel Drucker, MD, Is Still Unlocking Scientific Secrets
The Endocrine Society’s 2025 Fred Conrad Koch Lifetime Achievement Award recipient, Daniel Drucker, MD, first discovered his passion for science in high school when he learned “this is how stuff works.” He’s still learning to this day, and he tells Endocrine News about his ongoing scientific quests, the mentors who made a difference along the...People with Type 2 Diabetes Who Eat Low-Carb Diets May Be Able to Go Off Meds
Adults with type 2 diabetes on a low-carbohydrate diet may see benefits to their beta-cell function allowing them to better manage their disease and possibly discontinue medication, according to new research published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Beta-cells are endocrine cells in the pancreas that produce and release insulin, the hormone...
Community Service: How Joshua J. Joseph, MD, MPH, Is Leveling the Healthcare Playing Field for All
When his grandmother succumbed to a heart attack when he was only eight years old, Joshua J. Joseph, MD, MPH, was determined to end as much suffering as he could. The recipient of the Endocrine Society’s 2024 Richard E. Weitzman Outstanding Early Career Investigator Award, he details his ongoing endeavors to make sure Black Americans...Investigators Describe Changes to Pancreatic Beta-Cell at Onset of Type 1 Diabetes
New research by investigators at Joslin Diabetes Center sheds new light on the specific changes β-cells go through at the onset of type 1 diabetes. Their findings—published in Nature Cell Biology—offer new avenues for targeted interventions for the chronic autoimmune condition. “In the field of type 1 diabetes, research has largely focused on understanding the immune...
